North America Multiple Myeloma Therapeutics Market was worth USD 2.69 billion in 2018 and estimated to be growing at a CAGR of 4.37%, to reach USD 3.33 billion by 2023. North America dominated the market with highest revenue because of stability of key manufacturers in the region.
Several leading drugs are emerging in the market, mostly were approved over the past few years, and have enhanced median surviving rates by about 50%. The advancement of drug therapy and stem-cell relocation for the treatment of myeloma and the development of new agents has contributed in increasing the survival time for patients suffering from Myeloma.
Augmented demand of therapeutic products for the management of blood diseases is a key driver of the multiple myeloma therapeutic market. This market growth is also driven by increasing incidence of the disease cases, sustained success of revlimid and developing additional treatments. Though, inflexible regulations by several governments impede the growth of North America multiple myeloma therapeutic market.
The North America Multiple Myeloma Therapeutics Market is segmented on the basis of Treatment Type into Chemotherapy which is further segmented into Anthracycline Antibiotic (Melphalan (Alkeran), Liposomal doxorubicin (Doxil)) and Alkylating agent (Doxorubicin (Adriamycin), Cyclophosphamide (Neosar), Vincristine (Oncovin), Carmustine (BiCNU)) and Targeted Therapy ( Proteasome Inhibitor (Bortezomib (Velcade), Carfilzomib (Kyprolis)), by Drug Type into Corticosteroids (Dexamethasone (Decadron), Prednisone (Deltasone/Orasone)) and Immunomodulatory Agents (Thalidomide (Thalomid), Lenalidomide (Revlimid), Arsenic trioxide (Trisenox), Plerixafor (Mozobil)). With the advancement in technology targeted therapy is on a high growth due to its advantages over chemotherapy such as lesser side effects.
Based on geography the market is analysed under various regions namely, USA and Canada. USA is leading market for multiple myeloma therapeutics all over the globe and Canada is anticipated to grow at a high rate in the forecast period.
Some of the key contributors in the industry include AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc. ,Teva Pharmaceutical Industries Ltd. ,TG Therapeutics Inc. and Johnson and Johnson.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
5.1.1 Chemotherapy
5.1.1.1 Anthracycline antibiotic
5.1.1.2 Alkylating agent
5.1.2 Targeted Therapy
5.1.2.1 Proteasome inhibitor
5.2 By Drug Type
5.2.1 Corticosteroids
5.2.1.1 Dexamethasone (Decadron)
5.2.1.2 Prednisone (Deltasone/Orasone)
5.2.2 Immunomodulatory agents
5.2.2.1 Thalidomide (Thalomid)
5.2.2.2 Lenalidomide (Revlimid)
5.2.2.3 Arsenic trioxide (Trisenox)
5.2.2.4 Plerixafor (Mozobil)
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)
7.4.1 Failure Rate
7.4.2 Clinical Trial Duration
7.4.3 Clinical Trial
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AB Science SA
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 AbbVie Inc.
9.3 Ablynx NV
9.4 Acceleron Pharma Inc.
9.5 IGF Oncology LLC.
9.6 ImmunGene Inc.
9.7 Millennium Pharmaceuticals Inc.
9.8 MimiVax LLC
9.9 Mirna Therapeutics
9.10 RedHill Biopharma Ltd.
9.11 Rhizen Pharmaceuticals S.A.
9.12 Terpenoid Therapeutics Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
